ACLX vs. TWST, IMCR, DNLI, IOVA, VCEL, RXRX, SWTX, APGE, KYMR, and ADMA
Should you be buying Arcellx stock or one of its competitors? The main competitors of Arcellx include Twist Bioscience (TWST), Immunocore (IMCR), Denali Therapeutics (DNLI), Iovance Biotherapeutics (IOVA), Vericel (VCEL), Recursion Pharmaceuticals (RXRX), SpringWorks Therapeutics (SWTX), Apogee Therapeutics (APGE), Kymera Therapeutics (KYMR), and ADMA Biologics (ADMA). These companies are all part of the "biological products, except diagnostic" industry.
Arcellx (NASDAQ:ACLX) and Twist Bioscience (NASDAQ:TWST) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.
Arcellx has a net margin of -38.39% compared to Twist Bioscience's net margin of -69.24%. Arcellx's return on equity of -13.11% beat Twist Bioscience's return on equity.
Arcellx currently has a consensus price target of $78.73, indicating a potential upside of 46.82%. Twist Bioscience has a consensus price target of $42.50, indicating a potential downside of 9.59%. Given Arcellx's stronger consensus rating and higher possible upside, equities analysts plainly believe Arcellx is more favorable than Twist Bioscience.
Arcellx has a beta of 0.24, indicating that its share price is 76% less volatile than the S&P 500. Comparatively, Twist Bioscience has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500.
96.0% of Arcellx shares are held by institutional investors. 6.2% of Arcellx shares are held by company insiders. Comparatively, 3.9% of Twist Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Twist Bioscience received 43 more outperform votes than Arcellx when rated by MarketBeat users. However, 76.67% of users gave Arcellx an outperform vote while only 56.69% of users gave Twist Bioscience an outperform vote.
In the previous week, Arcellx had 14 more articles in the media than Twist Bioscience. MarketBeat recorded 19 mentions for Arcellx and 5 mentions for Twist Bioscience. Twist Bioscience's average media sentiment score of 0.74 beat Arcellx's score of 0.55 indicating that Twist Bioscience is being referred to more favorably in the news media.
Arcellx has higher earnings, but lower revenue than Twist Bioscience. Arcellx is trading at a lower price-to-earnings ratio than Twist Bioscience, indicating that it is currently the more affordable of the two stocks.
Summary
Arcellx beats Twist Bioscience on 14 of the 19 factors compared between the two stocks.
Get Arcellx News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACLX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
